|ADHIKARI, P - Mississippi State University|
|ROGIEWICZ, A - University Of Manitoba|
|KIM, W - University Of Georgia|
|Cox, Nelson - Nac|
|SLOMINSKI, B - University Of Manitoba|
Submitted to: Journal of Applied Poultry Research
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 6/20/2022
Publication Date: 6/26/2022
Citation: Adhikari, P., Rogiewicz, A., Kim, W.K., Cosby, D.E., Cox Jr, N.A., Slominski, B.A. 2022. Effect of enzyme-modified yeast products on Salmonella Enteritidis colonization in different organs of laying hens. Journal of Applied Poultry Research. https://doi.org/10.1016/j.japr.2022.100277.
Interpretive Summary: Foodborne illnesses continue to be important health and economic issues in the United States and abroad, with Salmonella enterica serovar Enteritidis being a leading cause of foodborne gastroenteritis in humans. Antibiotics and other antimicrobials have historically been used to improve animal health and growth. However, this practice has fallen out of popularity with the increased antimicrobial resistance of pathogenic bacteria. Other methods have been proposed to replace the antibiotic use as growth promoters. In addition to pre- and probiotics, yeast derived products have been found to promote animal health and growth. In this experiment, the effectiveness of two products (one derived from the yeast and cell walls of Sacchromyces Torula and the second from enzymatically modified yeast and cell walls of Sacchromyces Torula) a common yeast were evaluated for preventing the colonization of laying hens with Salmonella Enteritidis. Both yeast derived products were able to reduce Salmonella Enteritidis in the internal organs and ceca of the laying hens, with the enzymatically modified product having more effect on the recovery of Salmonella from the ceca.
Technical Abstract: A study was conducted to assess the effectiveness of yeast-derived products in the recovery of Salmonella Enteritidis (SE) in White Leghorns. Thirty-two hens were challenged both orally (OR) and intracloacally (IC) with nalidixic acid resistant SE (SENAR). Hens were individually housed in conventional wire laying cages and randomly allocated to four treatments with eight hens per replicate: 1) No SENAR challenge (T1: NC), 2) SENAR challenge (T2: PC), 3) SENAR challenge + a blend of Saccharomyces-Torula yeasts and yeast cell walls (T3; intact yeast), and 4) SENAR challenge + enzymatically-modified Saccharomyces-Torula yeasts and yeast cell walls (T4; modified yeast). The fecal samples were 100% positive for SENAR at 3 days post-inoculation (dpi) in T2, T3, and T4. By 6 dpi, fecal samples were 87, 62 and 37% positive for T2, T3, and T4, respectively. ens were euthanized at 7 dpi to harvest liver-gall bladder (L/GB), spleen, ovaries, and ceca. The recovery of SENAR in L/GB was 75, 25 and 37% in T2, T3, and T4 (P < 0.05), whereas that of the spleen was 62, 25 and 37% in T2, T3 and T4 (P < 0.05), respectively. T3 and T4 reduced SENAR counts (CFU/g) in ceca from 4.3 log10 to 2.7 and 1.95 log10, respectively, compared to T2 (P < 0.05). The cecal count of SENAR was 1.6 log10 lower in T3 and 2.3 log10 lower in T4 compared to T2. Both yeast derived products reduced Salmonella in internal organs and the ceca of laying hens. Enzymatically modified yeast (T4) was better than its intact counterpart (T3) in reducing Salmonella counts in the ceca.